Smith & Nephew CFO John Rogers to step down.


Medical technology firm Smith & Nephew said on Wednesday that John Rogers will step down from his role as chief financial officer on 30 September, to take up an external position in the US.

  • Smith & Nephew
  • 19 August 2026 08:20:12
Smith & Nephew

Source: Sharecast

The search for his successor has already been initiated and in the meantime, Senior Vice President Finance and Group Controller Pierre Palassian will serve as interim CFO.

Chief executive Deepak Nath said: "I would like to thank John for his many contributions over the last three years as we've delivered the 12-Point Plan, improved our financial performance and developed the RISE strategy. He has been a valued colleague and a highly regarded member of our Executive Committee."

Smith & Nephew said Palassian is a global finance leader with more than two decades of experience in finance leadership roles and has previously led the finance function for each of its Global Operations, R&D, Advanced Wound Management, Sports Medicine, International Markets and Emerging Markets organisations.

He joined the company in June 2017, having had senior roles at Abbvie and Abbott Laboratories.

At 0820 BST, the shares were down 3.5% at 1,071.98p.

See latest RNS on Investegate


Exchange: London Stock Exchange
Sell:
0.00
Buy:
0.00
Change: 4.81 ( 0.04 %)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.